Search: onr:"swepub:oai:lup.lub.lu.se:5483d236-c50f-424e-b2d9-b392aa880fd5" >
Increased remission...
Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study
-
- Juliusson, Gunnar (author)
- Östergötlands Läns Landsting,Linköpings universitet,Lund University,Lunds universitet,Stamcellscentrum (SCC),Avdelningen för stamcellsforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,Stem Cell Center,Division of stem cell research,Department of Laboratory Medicine,Faculty of Medicine,Hälsouniversitetet,Hematologi,Hematologiska kliniken US
-
Hoglund, M (author)
-
- Karlsson, K (author)
- Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Hematologi,Hematologiska kliniken US
-
show more...
-
Lofgren, C (author)
-
- Mollgard, L (author)
- Karolinska Institutet
-
- Paul, C (author)
- Karolinska Institutet
-
Tidefelt, U (author)
-
- Bjorkholm, M (author)
- Karolinska Institutet
-
show less...
-
(creator_code:org_t)
- 2003-11-19
- 2003
- English.
-
In: British Journal of Haematology. - : Wiley. - 0007-1048 .- 1365-2141. ; 123:5, s. 810-818
- Related links:
-
http://dx.doi.org/10...
-
show more...
-
https://onlinelibrar...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
http://kipublication...
-
https://urn.kb.se/re...
-
show less...
Abstract
Subject headings
Close
- Cladribine has single-drug activity in acute myeloid leukaemia (AML), and may enhance the formation of the active metabolite (ara-CTP) of cytosine arabinoside (ara-C). To evaluate the feasibility of adding intermittent cladribine to intermediate-dose ara-C (1 g/m(2)/2 h) b.i.d. for 4 d with idarubicin (CCI), we performed a 2:1 randomized phase II trial in AML patients aged over 60 years. Primary endpoints were time to recovery from cytopenia and need for supportive care following the first course. Sixty-three patients (median 71 years, range 60-84 years) were included, constituting 72% of all eligible patients. Toxicity was limited, with no differences between the treatment arms. The early toxic death rate was 11%. The median time to recovery from neutropenia and thrombocytopenia was 22 and 17 d from the start of course no. 1, respectively, and the requirement for platelet and red cell transfusions was four and eight units respectively. Patients had a median of 8 d with fever over 38degreesC, and 17 d with intravenous antibiotic treatment. The overall complete remission (CR) rate was 62%, with 51% CR from one course of CCI in comparison with 35% for the two-drug therapy (P = 0.014). The median survival with a 2-year follow-up was 14 months, and the 2-year survival was over 30%, with no differences between the treatment arms. Considering the median age and our population-based approach, the overall results are encouraging.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Keyword
- survival
- toxicity
- cladribine
- AML
- elderly
- MEDICINE
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
To the university's database